← 홈

CGT

1,235개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,235개
CGTBiologicstaleGerman Cancer Research CenterPhase 1

Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion (Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion)

Relapsed/Refractory Acute Myeloid Leukemia (AML) · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing Boren HospitalPhase 1

Dual CD33/CLL1 CAR T (Dual CD33/CLL1 CAR T)

Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBeijing BiotechPhase 2

Dual-target CAR-NK cell product (Dual-target CAR-NK cell product)

Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing GoBroad HospitalPhase 1

Dual-targeting BCMA-CD19 CAR-T cell infusion (Dual-targeting BCMA-CD19 CAR-T cell infusion)

Relapsed or Refractory Multiple Myeloma (RRMM) · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting CLDN18.2 and PD-L1 CAR-T cells (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

Advanced Solid Tumor · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting VEGFR1 and PD-L1 CAR-T cells (Dual-targeting VEGFR1 and PD-L1 CAR-T cells)

Malignant Peritoneal Effusion; Malignant Ascites · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of Kansas Medical Ce…Phase 1

DuoCAR20.19.22-D95 (DuoCAR20.19.22-D95)

B-Cell Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

E6 TCR (E6 TCR)

Vaginal Cancer; Cervical Cancer · Vaginal Cancer

#VaginalCancer#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 0%임상시험 1상태 ACTIVE
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

E7 TCR cells (E7 TCR cells)

Papillomavirus Infections; Cervical Intraepithelial Neoplasia · Papillomavirus Infections

#PapillomavirusInfections#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 5%임상시험 1상태 ACTIVE
CGTBiologicstaleBeijing BiotechPhase 2

EB-CAR30-NK (EB-CAR30-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EB-CAR5-NK (EB-CAR5-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EB-CARMSLN-NK (EB-CARMSLN-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

DLL3/CD56 CAR-NK cells (EB-DART-NK01, EB-DART-NK01 (DLL3/CD56 CAR-NK cells))

Small Cell Lung Cancer (SCLC); Relapsed/Refractory SCLC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CLDN182#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#CEA#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleBeijing BiotechPhase 2

EB-MF-CAR-NK-01 (EB-MF-CAR-NK-01)

Malignant Pleural Mesotheliomas · Malignant Pleural Mesotheliomas

#MalignantPleuralMesotheliomas#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING

41 / 62 페이지

← 이전다음 →